Ferroptosis Therapy for Parkinson's Disease

Therapeutic Category: Disease-Modifying Therapies | Neuroprotection Target: Ferroptosis pathway (GPX4, System Xc-, lipid peroxidation, iron metabolism) Indications: Parkinson’s Disease, Parkinsonism Syndromes Status: Preclinical to Clinical (Phase 2)

Pathway Diagram

flowchart TD
    N0["FERROPTOSIS"]
    N1["SLC7A11"]
    N1 -->|"inhibits"| N0
    N2["lipid_peroxidation"]
    N2 -->|"causes"| N0
    N3["GPX4"]
    N3 -->|"inhibits"| N0
    N3 -->|"inhibits"| N0
    N4["ACSL4"]
    N4 -->|"activates"| N0
    N5["NEURODEGENERATION"]
    N0 -->|"associated with"| N5
    N6["ROS"]
    N6 -->|"causes"| N0
    N6 -->|"activates"| N0
    N1 -->|"inhibits"| N0
    N3 -->|"inhibits"| N0
    N1 -->|"activates"| N0
    N7["NRF2"]
    N7 -->|"inhibits"| N0

Overview

Ferroptosis Therapy for Parkinson’s Disease represents a targeted neuroprotective strategy specifically addressing the iron-dependent, lipid peroxidation-driven cell death pathway implicated in dopaminergic neuron loss. Unlike general neuroprotective approaches, this therapy directly targets the molecular mechanisms of ferroptosis: glutathione peroxidase 4 (GPX4) dysfunction, System Xc- impairment, ACSL4 upregulation, and iron accumulation in the substantia nigra. ^{1Ferroptosis in Parkinson disease — The iron-related degenerative disease2024 · Nat Rev Neurol · PMID 39218077Open reference}

The rationale for ferroptosis-targeted therapy in PD stems from multiple converging lines of evidence: iron accumulation is a well-documented pathological hallmark of PD brains, lipid peroxidation markers are elevated in PD substantia nigra and cerebrospinal fluid, and GPX4 activity is compromised in PD models and patient tissue. ^{2GPX4 and ferroptosis in Parkinson's disease2024 · J Neurochem · DOI 10.1111/jnc.16123Open reference} This creates a “perfect storm” where dopaminergic neurons become exquisitely vulnerable to ferroptotic death.

Molecular Targets in Parkinson’s Disease

GPX4 (Glutathione Peroxidase 4)

GPX4 is the central regulator of ferroptosis and the primary therapeutic target in PD. Unlike other glutathione peroxidases, GPX4 directly reduces lipid hydroperoxides (LOOH) to corresponding alcohols (LOH), preventing iron-catalyzed lipid radical formation. In PD:

• Expression reduction: GPX4 is downregulated in PD substantia nigra ^{2GPX4 and ferroptosis in Parkinson's disease2024 · J Neurochem · DOI 10.1111/jnc.16123Open reference}

• Activity impairment: GPX4 enzymatic activity is reduced in PD models

• Selenocysteine vulnerability: The selenocysteine at GPX4’s active site makes it susceptible to oxidative damage

Therapeutic approaches to restore GPX4 function include:

• Direct GPX4 activators (e.g., ML210 derivatives)

• Selenoprotein synthesis enhancers (selenium supplementation)

• GPX4 mimetics that replicate lipid peroxide reduction

• N-acetylcysteine (NAC) to boost glutathione substrate availability

System Xc- (Cystine/Glutamate Antiporter)

The System Xc- (SLC7A11) is the cystine/glutamate antiporter that provides the cysteine substrate for glutathione synthesis. In PD:

• Expression reduction: System Xc- expression is downregulated in PD models ^{3System Xc- in neurodegeneration: cystine/glutamate antiporter as a therapeutic target2023 · Cell Death Dis · DOI 10.1038/s41419-023-05890-1Open reference}

• Function impairment: Cystine uptake is reduced, limiting glutathione synthesis

• Dopaminergic neuron vulnerability: These neurons rely heavily on System Xc- for redox homeostasis

Therapeutic approaches:

• N-acetylcysteine (NAC): Provides alternative cysteine source to bypass System Xc-

• Buthionine sulfoximine (BSO): Inhibitor used in research to induce ferroptosis (not therapeutic)

• Glutathione precursors: NAC, GSH esters

ACSL4 (Acyl-CoA Synthetase Long-Chain Family Member 4)

ACSL4 is an enzyme that incorporates long-chain polyunsaturated fatty acids into phospholipids, promoting lipid peroxidation. In PD:

• Upregulation: ACSL4 is elevated in PD dopaminergic neurons ^{4ACSL4 contributes to ferroptosis-induced dopaminergic neurodegeneration2023 · Cell Discov · DOI 10.1038/s41421-023-00504-6Open reference}

• Sensitivity driver: High ACSL4 expression sensitizes cells to ferroptosis

• Therapeutic target: ACSL4 inhibition protects against ferroptotic death

Therapeutic approaches:

• ACSL4 inhibitors: Development of small-molecule ACSL4 inhibitors

• Dietary modification: Reducing dietary PUFA intake

• Lipid metabolism modulators

FSP1 (Ferroptosis Suppressor Protein 1)

FSP1 (also known as AIFM2) is a coenzyme Q10-dependent ferroptosis suppressor that acts independently of GPX4. In PD:

• Protective role: FSP1 reduces ubiquinone to ubiquinol, which directly traps lipid peroxyl radicals

• Therapeutic potential: FSP1 activators could provide GPX4-independent neuroprotection ^{5FSP1 protects dopaminergic neurons from ferroptosis in PD models2024 · Mol Neurobiol · DOI 10.1007/s12035-024-06234-2Open reference}

Nrf2 (Nuclear Factor Erythroid 2-Related Factor 2)

Nrf2 is the master regulator of antioxidant response. In PD:

• Activation deficit: Nrf2 signaling is impaired in PD

• Downstream targets: Nrf2 regulates GPX4, SLC7A11, ferritin, and heme oxygenase-1

• Therapeutic target: Nrf2 activators can induce ferroptosis resistance genes ^{6Nrf2 activation protects against ferroptosis in Parkinson's disease2023 · Redox Biol · DOI 10.1016/j.redox.2023.102892Open reference}

Therapeutic Approaches

1. GPX4-Targeted Therapies

Direct GPX4 Activators

• ML210: Covalent GPX4 activator in preclinical development

• RSL3: GPX4 inhibitor (research tool, not therapeutic)

• Diallyl trisulfide (DATS): Releases H2S and activates GPX4

GPX4 Substrate Enhancement

• N-acetylcysteine (NAC): Glutathione precursor; improves GPX4 substrate availability

• Glutathione ethyl ester: Cell-permeable GSH

• Selenium supplementation: Supports selenocysteine incorporation into GPX4 ^{7Selenium and ferroptosis: insights into GPX4 regulation2016 · Nat Rev Neurosci · PMID 27339870Open reference}

2. System Xc- Modulators

• N-acetylcysteine (NAC): Bypasses System Xc- by providing alternative cysteine source

• Glutathione esters: Cell-penetrating GSH derivatives

• Dietary cystine: Increased dietary cystine intake

3. Direct Ferroptosis Inhibitors

Ferrostatins

• Ferrostatin-1: Prototypical ferroptosis inhibitor; chain-breaking lipid antioxidant

• Ferrostatin-2: Improved metabolic stability

• Liproxstatin-1: Highly potent ferroptosis inhibitor ^{8Ferrostatins inhibit oxidative cell death and neural degeneration2014 · J Am Chem Soc · PMID 25330157Open reference}

Mechanism

These compounds function as chain-breaking antioxidants that specifically trap lipid peroxyl radicals, preventing the propagation of lipid peroxidation. They are highly effective in preventing ferroptotic cell death in vitro and in vivo.

4. Lipid Metabolism Modulators

• Vitamin E (α-tocopherol): Chain-breaking antioxidant; blocks lipid peroxidation propagation

• ACSL4 inhibitors: Reduce PUFA incorporation into phospholipids

• PUFA reduction: Dietary modification to reduce ferroptosis susceptibility

5. Iron Chelation

Iron chelation therapy is covered in detail on the Iron Chelation Therapy for Parkinson’s Disease page. Key agents include:

6. Nrf2 Activators

• Sulforaphane: Potent Nrf2 activator; induces antioxidant response genes

• Dimethyl fumarate (Tecfidera): FDA-approved Nrf2 activator

• ** Bardoxolone methyl**: Nrf2 activator in clinical trials for neurodegenerative diseases

Preclinical Evidence in Parkinson’s Disease Models

In Vitro Evidence

1. GPX4 downregulation: GPX4 expression is reduced in PD patient-derived neurons and mouse models

2. Ferroptosis induction: Pharmacological GPX4 inhibition (RSL3) induces dopaminergic neuron death

3. Neuroprotection: Ferrostatin-1 and liproxstatin-1 protect dopaminergic neurons from ferroptotic death

4. Iron chelation: Deferoxamine and deferiprone reduce ferroptotic cell death in vitro

5. NAC efficacy: NAC protects against System Xc- inhibition-induced ferroptosis

In Vivo Evidence

1. Animal models: GPX4 knockout mice develop progressive neurodegeneration ^{9Neurodegeneration in GPX4-deficient mouse models2014 · Nat Neurosci · PMID 24848240Open reference}

2. Iron chelation: Deferiprone reduces dopaminergic neuron loss in MPTP models

3. Ferrostatins: Lipophilic ferrostatins cross the BBB and protect against 6-OHDA toxicity

4. System Xc-: Genetic or pharmacological inhibition of System Xc- induces parkinsonian phenotype

5. ACSL4: ACSL4 knockout or inhibition protects against dopaminergic degeneration

Key Studies

• Li et al., Ferroptosis in Parkinson disease (Nat Rev Neurol, 2024)

• Zhang et al., GPX4 and ferroptosis in Parkinson’s disease (J Neurochem, 2024)

• Ayton et al., Ferroptosis contributes to dopaminergic neuron loss (Brain, 2022)

• Do Van et al., Ferroptosis in Parkinson’s disease (Mov Disord, 2016)

Clinical Trials in Parkinson’s Disease

Completed and Active Trials

FAIRPARK-II Trial Results

The FAIRPARK-II trial (NCT02655333) evaluated deferiprone in 262 Parkinson’s disease patients with motor complications: ^{2GPX4 and ferroptosis in Parkinson's disease2024 · J Neurochem · DOI 10.1111/jnc.16123Open reference}0

Results:

• Primary endpoint: Significant reduction in iron in the substantia nigra (R2* MRI)

• Secondary endpoints: Mixed results on clinical outcomes (MDS-UPDRS)

• Safety: Agranulocytosis monitoring required (serious adverse event management protocol)

• Interpretation: Validated iron chelation as a disease-modifying approach; iron reduction achieved but clinical benefit uncertain

Ongoing Research

• GPX4 activators: Preclinical development of brain-penetrant GPX4 direct activators

• Ferrostatins: Optimization of pharmacokinetics for CNS penetration

• Combination approaches: Iron chelation + ferroptosis inhibitors + standard of care

• Biomarker development: Identifying patients most likely to benefit from ferroptosis-targeted therapy

Biomarkers for Patient Selection

Ferroptosis Biomarkers

Patient Selection Criteria

• Elevated iron markers (serum ferritin, CSF iron)

• Reduced GPX4 activity

• High lipid peroxidation burden

• Early disease stage (before extensive neuron loss)

• MRI evidence of iron accumulation in substantia nigra

Combination Strategies

Rationale for Combination Therapy

Ferroptosis in PD involves multiple converging pathways. Targeting multiple mechanisms may provide synergistic benefit:

1. Iron chelation + ferroptosis inhibitors: Address iron accumulation AND lipid peroxidation

2. GPX4 activation + Nrf2 activation: Enhance both direct and indirect antioxidant capacity

3. System Xc- support + GSH precursor: Maximize glutathione availability

4. Standard of care + neuroprotection: Combine with dopaminergic therapies

Promising Combinations

Cross-Linking to Related Pathways

Connected Mechanisms

• Oxidative Stress Response: Ferroptosis is fundamentally an oxidative stress pathway

• Iron Metabolism: Central to both normal neuronal function and ferroptosis

• Mitochondrial Dysfunction: Mitochondria are major sources of lipid peroxides

• Neuroinflammation: Microglial activation can promote ferroptosis

• Alpha-Synuclein Aggregation: Iron interacts with alpha-synuclein to promote aggregation

Related Therapeutic Pages

• Iron Chelation Therapy for Parkinson’s Disease

• Ferroptosis Modulation Therapy (general)

• Ferroptosis in Parkinson’s Disease (mechanism)

• Nrf2 Activators for Parkinson’s Disease

• CoQ10 for Parkinson’s Disease

• Neuroprotection

Related Gene/Protein Pages

• GPX4

• SLC7A11 (System Xc-)

• ACSL4

• FSP1

• Nrf2

• Ferritin

Challenges and Future Directions

Current Limitations

1. BBB penetration: Many ferroptosis inhibitors (e.g., ferrostatin-1) have limited CNS exposure

2. Biomarker validation: No validated ferroptosis biomarkers for patient selection

3. Optimal timing: Unknown when in disease course ferroptosis-targeted therapy is most effective

4. Combination optimization: Unknown best combination strategy

5. Safety monitoring: Iron chelation requires careful monitoring (agranulocytosis, organ toxicity)

Emerging Strategies

1. Brain-penetrant ferrostatins: Next-generation ferrostatins with improved pharmacokinetics

2. Gene therapy: AAV-mediated GPX4 or FSP1 expression

3. Targeted delivery: Nanoparticle-based delivery of ferroptosis inhibitors

4. Personalized medicine: Genotype-guided ferroptosis modulation

5. Biomarker-driven trials: Selection of patients with elevated ferroptosis markers

Future Directions

• Phase 2/3 trials of brain-penetrant ferroptosis inhibitors

• Combination trials of iron chelation + ferroptosis inhibition

• Biomarker-driven patient selection trials

• Gene therapy approaches for GPX4/FSP1 expression

• Early intervention trials in prodromal PD

See Also

• Ferroptosis in Parkinson’s Disease

• Iron Chelation Therapy for Parkinson’s Disease

• Ferroptosis Modulation Therapy

• GPX4 Gene

• SLC7A11 Gene

• ACSL4 Gene

• Oxidative Stress in Parkinson’s Disease

External Links

• Ferroptosis in Parkinson’s Disease - Nature Reviews Neurology

• GPX4 and ferroptosis in PD - Journal of Neurochemistry

• FAIRPARK-II Trial Results

• Clinical Trials - Ferroptosis and Parkinson’s Disease